{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"47.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"An ASAS 40 response is defined as \\>=40% improvement from baseline in 3 of 4 domains: patient's global assessment of disease activity (0=very well, 10=very poor), total back pain (0=no pain, 10=most severe pain), function (self-assessment using BASFI (0=no functional impairment to 10=maximal impairment), inflammation (0=none, 10=very severe) with an absolute improvement of at least 2 (0-10 cm VAS), and no deterioration in the remaining domain.","groups":[{"description":"Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.","id":"OG000","title":"Group 1: Placebo Then Golimumab"},{"description":"Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.","id":"OG001","title":"Group 2: Golimumab"}],"paramType":"NUMBER","populationDescription":"FAS included all participants who were randomized in the study.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"Percentage of Participants Who Achieved at Least 40 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 40) at Week 16","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}